These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday.
Revance Therapeutics, Inc.（納斯達克股票代碼：AKAM）週四公佈了第一季度虧損。
Revance Therapeutics posted a GAAP loss of 54 cents per share, compared to market expectations for a loss of 63 cents per share. The company's quarterly sales came in at $51.936 million versus estimates of $56.634 million, according to data from Benzinga Pro.
Revance Therapeutics公佈的每股GAAP虧損爲54美分，而市場預期的每股虧損爲63美分。根據Benzinga Pro的數據，該公司的季度銷售額爲5193.6萬美元，而預期爲5,663.4萬美元。
"We are very pleased to see the DAXXIFY strategy change continue to drive the desired momentum and market share gains. Notably, we saw a healthy uptick in volume both on a year-on-year basis, where aesthetic units sold increased by 105%, and on a sequential quarterly basis where aesthetic units sold increased by 7% despite traditional Q4 to Q1 seasonality. The positive impact of our strategy change was further reflected in our market share gains where DAXXIFY's share increased from 3.0% in Q4'23 to 3.7% in Q1'24.1 DAXXIFY's net revenue was $22.1 million for the quarter, after a reduction of $2.0 million related to a consumer coupon program. In addition, the RHA Collection continued to outpace the market growing share from 9.1% in Q4'23 to 9.8%1 in Q1'24, against the backdrop of a soft filler market," said Mark J. Foley, President and Chief Executive Officer.
“我們很高興看到DAXXIFY的戰略變化繼續推動預期的勢頭和市場份額的增長。值得注意的是，我們的銷量同比增長良好，美學單位的銷量增長了105％，而美學單位的銷量連續季度增長了7％，儘管有傳統的第四季度至第一季度的季節性。我們的戰略變更的積極影響進一步反映在我們的市場份額增長上，DAXXIFY的份額從23年第四季度的3.0％增加到24年第一季度的3.7％。在與消費者優惠券計劃相關的200萬美元之後，DAXXIFY本季度的淨收入爲2,210萬美元。此外，在軟填料市場的背景下，RHA系列繼續超過市場增長份額，從23年第四季度的9.1％增至24年第一季度的9.8％1。” 總裁兼首席執行官馬克·弗利說。
Revance continues to expect 2024 total net product revenue, which includes sales of DAXXIFY and RHA collection, to be at least $280 million.
Revance繼續預計，2024年的總淨產品收入，包括DAXXIFY和RHA系列的銷售，將達到至少2.8億美元。
Revance Therapeutics shares rose 0.5% to close at $4.29 on Thursday.
週四，Revance Therapeutics股價上漲0.5％，收於4.29美元。
These analysts made changes to their price targets on Revance Therapeutics following earnings announcement.
業績公佈後，這些分析師調整了Revance Therapeutics的目標股價。
- Needham cut the price target on Revance Therapeutics from $18 to $12. Needham analyst Serge Belanger maintained a Buy rating.
- Mizuho slashed the price target on Revance Therapeutics from $9 to $8. Mizuho analyst Vamil Divan maintained a Neutral rating.
- 尼德姆將Revance Therapeutics的目標股價從18美元下調至12美元。尼德姆分析師塞爾吉·貝蘭格維持買入評級。
- 瑞穗將Revance Therapeutics的目標股價從9美元下調至8美元。瑞穗分析師瓦米爾·迪萬維持中性評級。
Read More: Top 2 Materials Stocks That Could Blast Off This Quarter
閱讀更多：本季度可能暴跌的兩大材料股